for at least 2 weeks.
3. The use as claimed in claim 1 or 2, wherein the blood plasma
fulvestrant concentration attained is at least 2.5 ngml-1 for at
least 2 weeks.
4. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises
fulvestrant, 30% or less weight of a pharmaceuticallyacceptable alcohol per volume of formulation, at least 1%
weight of a pharmaceutically-acceptable non-aqueous ester
solvent miscible in a ricinoleate vehicle per volume of formulation